Solid Tumor, Adult Clinical Trials in Huntersville, North Carolina

5 studies are recruiting for solid tumor, adult in Huntersville, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. First In Human Study of CX-2051 in Advanced Solid Tumors

   The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina BioOncology Institute, PLLC, Huntersville, North Carolina

   Locations

   8 in total

   Run by

   CytomX Therapeutics

   See if you can join NCT06265688 on ClinicalTrials.gov

2. First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

   A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site USA03, Huntersville, North Carolina

   Locations

   36 in total

   Run by

   DualityBio Inc.

   See if you can join NCT06554795 on ClinicalTrials.gov

3. A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

   Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers. The preliminary objective of this study is aimed at selecting PD-1+ and CTLA4+ T cells and other cellular fractions from peripheral bl…

   Stage

   Not phased

   Ages

   5 and older

   Site

   Carolina BioOncology Institute, Huntersville, North Carolina

   Run by

   BioCytics, Inc.

   See if you can join NCT00571389 on ClinicalTrials.gov

4. A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

   The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina BioOncology Institute, Huntersville, North Carolina

   Locations

   41 in total

   Run by

   Corbus Pharmaceuticals Inc.

   See if you can join NCT06265727 on ClinicalTrials.gov

5. Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

   TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with solid tumors. In cancer cells, rapid and upregulated DNA replication creates high replication stress, as such, cancer cells are more susceptible than n…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina BioOncology Institute, Huntersville, North Carolina

   Locations

   2 in total

   Run by

   Trethera

   See if you can join NCT05055609 on ClinicalTrials.gov